.avif)
.avif)
.avif)
Priovant Therapeutics Email Format
Biotechnology Research
・
51-200 employees
・
Durham, NC, USA
Priovant Therapeutics is a clinical-stage biotechnology company developing novel therapies for severe autoimmune diseases with significant unmet patient needs.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@priovanttx.com
Company Overview
Industry
Biotechnology Research
Headquarters
Durham, NC, USA
Revenue
$25M-$50M
FUNDING Stage
Private
Website
Key Executives
Benjamin Zimmer (Chief Executive Officer), Austin Gromatzky (Chief Financial Officer), Daniel Herz-Roiphe (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Priovant Therapeutics?
Priovant Therapeutics uses the first.last format on priovanttx.com, so Jane Smith would be jane.smith@priovanttx.com.
What autoimmune disease indications is Priovant Therapeutics currently targeting with brepocitinib?
Priovant Therapeutics is advancing brepocitinib, a dual TYK2/JAK1 inhibitor, across several autoimmune indications including dermatomyositis, non-infectious uveitis, lichen planopilaris, and cutaneous sarcoidosis, all areas with high unmet need and few approved therapies.
How did Priovant Therapeutics come to be formed?
Priovant Therapeutics was established in September 2021 through a transaction between Roivant Sciences and Pfizer, in which Pfizer licensed global development rights and US and Japan commercial rights to brepocitinib to Priovant.
Where is Priovant Therapeutics headquartered and how large is the company?
Priovant Therapeutics is headquartered in Durham, NC, and has approximately 119 employees. You can use Clay to build a targeted list of contacts there and verify individual email addresses before reaching out.
What is the status of Priovant Therapeutics' FDA review for brepocitinib in dermatomyositis?
The FDA accepted Priovant Therapeutics' New Drug Application for brepocitinib in dermatomyositis and granted Priority Review, with a PDUFA target action date in the third quarter of 2026 and a US launch expected at the end of September 2026.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating